# Study of ACR-2316 in Specific Advanced Solid Tumors

Source: https://onco.cc/trials/nct06667141/  
OnCo record `nct06667141` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ACR-2316 run by Acrivon Therapeutics, now recruiting.

## Summary

Study of ACR-2316 in Specific Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06667141 by Acrivon Therapeutics, with 100 participants planned, started 2024-10-08. Conditions recorded: Specific Advanced Solid Tumors. Interventions recorded: ACR-2316.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06667141
- Phase: 1/2
- Setting: ACR-2316-101: Phase 1/2 Study of ACR-2316 in Subjects With Advanced Solid Tumors
- Sponsor: Acrivon Therapeutics
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06667141: https://clinicaltrials.gov/study/NCT06667141

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [ACR-2316](https://onco.cc/drugs/acr-2316/)
- companies: [Acrivon Therapeutics](https://onco.cc/companies/acrivon-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06667141.json